Search 

OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)

OROX BioSciences is an early-stage biotech startup involved in discovery/development of small molecules capable of treating fibrosis, inflammation, and oncology.

Investment bank focused on Nordic Life Science companies

We are Petrone Group Asia Pacific , a Petrone Group ( www.petrone.it ) sister company dedicated to Global Comparators sourcing for clinical trials to China and APAC region.

We give support to Sponsors , CROs , Clinical Research Institutes , Pharma and Biotech company for IMP management and Comparators sourcing.

Our service has high flexibility in managing clinical trials from phase I to phase IV according to customers’ specific requirements.

To have a better idea of our Global sourcing capabilities please find below a recap of Petrone Group Headquarters and branches

HQ Italy
Euromed , Italian comparator drugs

EU Branches
BCN FARMA Spain / Spanish comparator drugs
PHD Pharmaceuticals / Irish and EU comparator drugs

US Branch
Euromed Pharma NY / US and Canada comparator drugs

Asia Pacific Branch
Petrone Group Asia Pacific Singapore / Asia Pacific and Australia comparator drugs

PHASTAR is a global biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.

Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,700 years accumulated technical experience across the company.

PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across five continents.

PhysioCue is digital health and therapy device development company, located in the heart of Silicon Valley, California. PhysioCue has developed the thermal neurostimulation technology for a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial diseases that Pleiogenix is targeting are acute alcoholic hepatitis (AAH), COVID-19, and non-alcoholic steatohepatitis (NASH) / Fibrosis, with additional diseases to follow. AAH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. NASH is a severe form of the chronic liver disease, non-alcoholic fatty liver disease (NAFLD). The AAH market is estimated to be $575 million by 2023, while the NASH market is estimated to be $35-40 billion by 2025. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; there have been ~34 million cases resulting in over 1,000,000 deaths (globally). There are no approved therapeutics that prevent or treat AAH, NASH, or COVID-19. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic and metabolic clinical benefits. In patients suffering from AAH, NASH, and COVID-19, inflammation is severely increased, and adiponectin is reduced in patients with NASH. Increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical for AAH, NASH / fibrosis, and/or COVID-19.

Imagine a world without Musculoskeletal Disorders (MSD) like back pain and tennis elbow!

This is the vision of PRECURE! 80 million people in the EU suffer from MSD, leading to €39 billion in employer costs, and more than €80 billion in societal costs. PRECURE provide an integrated solution for insurers and companies to help prevent MSD, reduce costs and create healthier workplaces. Our smart wearables measure employees physical activities throughout the workday. The data helps the employee reduce the muscle load, enables the company to remove the causes, and for the insurer to reduce claims. This is win for the individual, employer, insurer, and society.

The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.
We empower our clients in life science to establish biological knowledge through efficient reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy and commitment empower us to be creative and quality focused. A trusted partner with deeply rooted scientific experience.